Zelira Therapeutics Gains Momentum with FDA
Company Announcements

Zelira Therapeutics Gains Momentum with FDA

Zelira Therapeutics (AU:ZLD) has released an update.

Zelira Therapeutics has announced a significant step in advancing its HOPE® autism drug program after a promising meeting with the U.S. FDA where they received positive feedback and guidance on their Investigational New Drug (IND) submission. The meeting clarified the treatment indication and study design for their drug targeting irritability associated with Autism Spectrum Disorder. Poised for progress, Zelira anticipates further FDA correspondence to guide their IND process.

For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskZelira Therapeutics’ Financials: Borrowings Boost Cash Flow
TipRanks Australian Auto-Generated NewsdeskZelira Therapeutics Advances in FDA Trials and Product Development
TipRanks Australian Auto-Generated NewsdeskZelira Therapeutics Schedules Hybrid 2024 AGM
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App